AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q4 2025
580
Period ended Dec 31, 2025
Change on a year earlier
-10.2%
646 in Q4 2024
History
23 quarters
Since Q2 2020
Sources
23
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up eye care portfolio [folded into all other in q1 2026] — worldwide net revenues ($m)
- Eye Care Portfolio [folded into All Other in Q1 2026] — U.S. net revenues ($M)286 · Q4 2025
- Eye Care Portfolio [folded into All Other in Q1 2026] — International net revenues ($M)294 · Q4 2025
- Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide reported growth YoY (%)-10.1% · Q4 2025
- Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide operational (constant-currency) growth YoY (%)-11.0% · Q4 2025
- Ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M)128 · Q4 2025
- Lumigan/Ganfort (bimatoprost) — Worldwide net revenues ($M)104 · Q4 2025
- Alphagan/Combigan (brimonidine) — Worldwide net revenues ($M)54 · Q4 2025
- Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide net revenues ($M)114 · Q4 2024
- Other Eye Care — Worldwide net revenues ($M)294 · Q4 2025
Cite this data
StockData. (2026). AbbVie Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M) ($M), quarterly Q2 2020–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta_eye_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.